Investigational Cancer Vaccine Galinpepimut-S Receives Orphan Drug Status in EU for Multiple Myeloma
SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS)…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Leukogene Therapeutics Awarded $2M to Advance Compound for Treatment-resistant Multiple Myeloma
Leukogene Therapeutics, a startup company from the…
Baseball Greats, Amgen Launch Multiple Myeloma Awareness Campaign
Backed by former Major League Baseball All-Stars Dave…
Darzalex Combination Approved in Europe for Some Newly Diagnosed Multiple Myeloma Patients
The European Commission has approved the anti-CD38 antibody Darzalex…
Poseida’s Potential CAR T-cell Therapy Shows Positive Early Results in Phase 1 Multiple Myeloma Trial
Poseida Therapeutics’ CAR T-cell therapy candidate P-BCMA-101…
Some with Smoldering Multiple Myeloma May Benefit from Immediate Treatment, Study Suggests
Smoldering multiple myeloma (SMM) — an early, asymptomatic precursor…
